
|Videos|October 28, 2013
Dual Targeting of the HER2 Receptor
Author(s)Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.
Advertisement
Clinical Pearls
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.
- Dual targeting of the HER2 receptor proved to better than single targeting, resulting in an improvement in pathological complete remission
- Presence of a pathological complete remission correlated with increased disease-free survival and overall survival in patients with hormone receptor-positive and hormone receptor-negative disease
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































